WeightWatchers announced its Q2 2025 results, marked by the successful completion of a strategic reorganization that reduced debt by $1.15 billion. The company reported combined revenues of $189 million, a 6% decrease year-over-year, primarily due to headwinds in the Behavioral business. However, Clinical revenues saw a significant 55% increase, driven by compounded semaglutide subscriptions. Combined End of Period Subscribers declined by 17% year-over-year.
Successfully completed a strategic reorganization, reducing debt by $1.15 billion.
Combined revenues for Q2 2025 were $189 million, a 6% decrease compared to the prior year.
Clinical revenues grew by 55% to $31 million, primarily driven by compounded semaglutide subscriptions.
Combined End of Period Subscribers decreased by 17% year-over-year to 3.2 million.
For the full fiscal year 2025, WeightWatchers expects total combined revenues to be between $685 million and $700 million, and Adjusted EBITDA to be between $140 million and $150 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance